Inhibition of IL-1β Improves Fatigue in Type 2 Diabetes
| Autor: | Adriano Fontana, Romana Furrer, Andrea Babians-Brunner, Heidemarie Gast, Marc Y. Donath, Iris K. Penner, Cornelia Keller, Claudia Cavelti-Weder, Alan M. Solinger |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Diabetes Care Electronic Pages
medicine.medical_specialty Endocrinology Diabetes and Metabolism Interleukin-1beta Type 2 diabetes Antibodies Monoclonal Humanized Systemic inflammation Proinflammatory cytokine 03 medical and health sciences 0302 clinical medicine Double-Blind Method Downregulation and upregulation Diabetes mellitus Internal medicine Internal Medicine medicine Humans Online Letters: Observations Prediabetes 030304 developmental biology Advanced and Specialized Nursing 0303 health sciences business.industry Interleukin medicine.disease 3. Good health Endocrinology Diabetes Mellitus Type 2 Immunology Tumor necrosis factor alpha medicine.symptom business 030217 neurology & neurosurgery |
| Zdroj: | Diabetes care Diabetes Care |
| ISSN: | 1935-5548 0149-5992 |
| Popis: | Several diseases including microbial infection, rheumatoid arthritis, multiple sclerosis, and cancer have been linked to fatigue. They all have in common an upregulation of cytokines, including interleukin (IL)-1β and tumor necrosis factor-α (TNF-α), which may interfere with clock gene functions (1). Increasing evidence associates type 2 diabetes with inflammatory processes characterized by elevated production of proinflammatory cytokines and infiltration of immune cells. Reducing IL-1 activity in prediabetes and diabetes improves insulin secretion, glycemic control, and markers of systemic inflammation (2–4). Given this background, we hypothesized that fatigue levels may be increased in type 2 diabetes and may be improved by IL-1β antagonism. Within a placebo-controlled, double-blind study of IL-1β antagonism with a monoclonal anti–IL-1β … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|